These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37614090)
21. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion. Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552 [TBL] [Abstract][Full Text] [Related]
22. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ilie M; Long-Mira E; Bence C; Butori C; Lassalle S; Bouhlel L; Fazzalari L; Zahaf K; Lalvée S; Washetine K; Mouroux J; Vénissac N; Poudenx M; Otto J; Sabourin JC; Marquette CH; Hofman V; Hofman P Ann Oncol; 2016 Jan; 27(1):147-53. PubMed ID: 26483045 [TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression in NSCLC: Role of cell blocks and concordance between samples. Ambrosini-Spaltro A; Dubini A; Pieri F; Ravaglia C; Delmonte A; Poletti V Diagn Cytopathol; 2021 Feb; 49(2):303-310. PubMed ID: 33091231 [TBL] [Abstract][Full Text] [Related]
24. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients. Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734 [TBL] [Abstract][Full Text] [Related]
25. PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. Vigliar E; Malapelle U; Iaccarino A; Acanfora G; Pisapia P; Clery E; De Luca C; Bellevicine C; Troncone G J Clin Pathol; 2019 Jun; 72(6):412-417. PubMed ID: 30846480 [TBL] [Abstract][Full Text] [Related]
26. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma. Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069 [TBL] [Abstract][Full Text] [Related]
27. A new AI-assisted scoring system for PD-L1 expression in NSCLC. Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765 [TBL] [Abstract][Full Text] [Related]
28. Among Multiple Needle Core Biopsy Samples, the One with the Highest Tumor Proportion Score Best Represents the PD-L1 Status of the Whole Surgical Specimen in Non-Small Cell Lung Cancer. Sun W; Yang X; Wang H; Wu J; Chen M; Liu C; Hu D; Huang X; Jia L; Kang Q; Wu Q; Diao X; Zhou L; Lin D Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):190-196. PubMed ID: 34753887 [TBL] [Abstract][Full Text] [Related]
30. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study. Russell PA; Farrall AL; Prabhakaran S; Asadi K; Barrett W; Cooper C; Cooper W; Cotton S; Duhig E; Egan M; Fox S; Godbolt D; Gupta S; Hassan A; Leslie C; Leong T; Moffat D; Qiu MR; Sivasubramaniam V; Skerman J; Snell C; Walsh M; Whale K; Klebe S Pathology; 2023 Dec; 55(7):922-928. PubMed ID: 37833206 [TBL] [Abstract][Full Text] [Related]
31. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score? Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885 [TBL] [Abstract][Full Text] [Related]
32. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485 [TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471 [TBL] [Abstract][Full Text] [Related]
34. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. Gompelmann D; Sinn K; Brugger J; Bernitzky D; Mosleh B; Prosch H; Geleff S; Blessing A; Tiefenbacher A; Hoetzenecker K; Idzko M; Hoda MA J Cancer Res Clin Oncol; 2023 May; 149(5):1747-1754. PubMed ID: 35708777 [TBL] [Abstract][Full Text] [Related]
35. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245 [TBL] [Abstract][Full Text] [Related]
36. Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores. Lea D; Zaharia C; Søreide K Cancer Treat Res Commun; 2024; 38():100788. PubMed ID: 38150845 [TBL] [Abstract][Full Text] [Related]
37. Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. Kuempers C; van der Linde LIS; Reischl M; Vogel W; Stellmacher F; Reck M; Heigener D; Rabe KF; Kirfel J; Perner S; Welker L Virchows Arch; 2020 Feb; 476(2):261-271. PubMed ID: 31392467 [TBL] [Abstract][Full Text] [Related]
38. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer. Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233 [TBL] [Abstract][Full Text] [Related]
39. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists. Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261 [TBL] [Abstract][Full Text] [Related]
40. Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas. Bigras G; Mairs S; Swanson PE; Morel D; Lai R; Izevbaye I Appl Immunohistochem Mol Morphol; 2018; 26(10):701-708. PubMed ID: 30095468 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]